opdualag
bristol-myers squibb pharma eeig - nivolumab, relatlimab - melanom - antineoplastic agents, monoclonal antibodies - opdualag is indicated for the first line treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older with tumour cell pd l1 expression < 1%.
mezavant 1200 mg
takeda pharmaceuticals international ag ireland branch - mesalazin - enterodepottablett - 1200 mg
naloxon hameln 0.4 mg/ ml
hameln pharma gmbh - naloksonhydrokloriddihydrat - injeksjons-/infusjonsvæske, oppløsning - 0.4 mg/ ml
carmustine macure 100 mg
macure pharma aps - karmustin - pulver og væske til konsentrat til infusjonsvæske, oppløsning - 100 mg
cidofovir macure 75 mg/ ml
macure pharma aps - sidofovirdihydrat - konsentrat til infusjonsvæske, oppløsning - 75 mg/ ml
foskarnetnatriumheksahydrat tillomed 24 mg/ ml
tillomed pharma gmbh - schönefeld - foskarnetnatriumheksahydrat - infusjonsvæske, oppløsning - 24 mg/ ml
fenylefrin unimedic 0.05 mg/ ml
unimedic pharma ab - fenylefrinhydroklorid - injeksjonsvæske, oppløsning - 0.05 mg/ ml
fenylefrin unimedic 0.1 mg/ ml
unimedic pharma ab - fenylefrinhydroklorid - injeksjonsvæske, oppløsning - 0.1 mg/ ml
teriparatide sun
sun pharmaceutical industries europe b.v. - teriparatide - osteoporosis; osteoporosis, postmenopausal - kalsiumhomeostase - teriparatide sun is indicated in adults. treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture (see section 5. in postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures has been demonstrated. treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture (see section 5.
resolor
takeda pharmaceuticals international ag ireland - prucalopride succinate - forstoppelse - andre stoffer for forstoppelse - resolor er indisert for symptomatisk behandling av kronisk forstoppelse hos voksne som laksemidler ikke gir tilstrekkelig lindring.